Collagen Solutions has reported H1/19 (year end March) results demonstrating strong commercial progress with nine new customer contracts signed and initiation of supply to 16 new customers. Within the period revenues grew by 13% despite the previously disclosed Korean contract expiration. Collagen Solutions continues to make progress with ChondroMimetic, with the final data submission for CE Mark expected to be submitted by year-end. We maintain our Buy recommendation.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: Collagen Solutions Plc - Commercial progress
- Published:
04 Dec 2018 -
Author:
Chris Donnellan -
Pages:
7
Collagen Solutions has reported H1/19 (year end March) results demonstrating strong commercial progress with nine new customer contracts signed and initiation of supply to 16 new customers. Within the period revenues grew by 13% despite the previously disclosed Korean contract expiration. Collagen Solutions continues to make progress with ChondroMimetic, with the final data submission for CE Mark expected to be submitted by year-end. We maintain our Buy recommendation.